Iconography : Life expectancy benefits of cancer screening in the end-stage renal disease population 来自 onAcademic 喜欢 0 阅读量: 16 作者:CJ Lebrun,LF Diehl,KC Abbott,PG Welch,CM Yuan DOI: 10.1016/s0272-6386(00)70332-5 被引量: 46 ...
Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237–43.LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM: Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis 35:237- ...
For each patient, an index date was defined as the first admission that occurred at or within four weeks of date of cancer diagnosis, with the index cancer as the primary diagnosis. Where no such admission was identifiable, index date was the date of cancer diagnosis on the NZCR. Level ...
9Seattle Cancer Care Alliance, Seattle, WA, USA; 10University of Colorado HSC, Aurora, CO, USA; 11Charite´ Universita¨tsmedizin Berlin, Berlin, Germany; 12Elbeklinikum Buxtehude, Buxtehude, Germany; 13Cancer Research UK Clinical Centre, Southampton, UK; 14Royal Free Hospital, London, UK; ...
End-stage renal disease (ESRD) poses a major global public health threat. The number of patients using renal replacement therapy has been estimated to at least double globally by 2030, with the most rapid increase occurring in Asia [1]. Due to complicating factors such as late referrals and ...
Rates of psychiatric conditions common to end-stage cancer patients (delirium, depression, anxiety disorders) remain unchanged. However, patient numbers have increased as the population has aged; indeed, cancer is a chief cause of mortality and morbidity
Exclusion criteria included central nervous system involvement of the cancer, severe cardiovascular illness, untreated hypertension, abnormal hepatic or renal function, diabetes, lifetime history of schizophrenia, bipolar disease, other psychotic illness, and anxiety or affective disorders within 1 year prior...
More than 50% of all reported clinical trials for gene therapy are for cancer. Objectives: To test the tolerability, safety, and recommended phase II dose of Allvec-1, a highly selective gene therapy vector, after systemic administration in patients with advanced stage IV solid tumor ...
2013. "Estimating the Long Term Impact of Kidney Donation on Life Expectancy and End Stage Renal ... BA Kiberd - Transplantation Research,2,1(2013-02-16) 被引量: 30发表: 2013年 Experience with a Two-Staged Pedicled Flexor Tendon Graft A two-staged technique for flexor tendon grafting in...
most significant predictors of chemoresistant HER2-negative breast cancer, contrasting with the sole independent predictor of a high PD-L1 level in HER2-positive breast cancer. Our study implies that the implementation of immune checkpoint inhibitors in these patient groups has the potential to enhance...